FATE vs. ALEC, EXAI, VALN, CCCC, TSHA, HUMA, ALLO, PRME, PROK, and EDIT
Should you be buying Fate Therapeutics stock or one of its competitors? The main competitors of Fate Therapeutics include Alector (ALEC), Exscientia (EXAI), Valneva (VALN), C4 Therapeutics (CCCC), Taysha Gene Therapies (TSHA), Humacyte (HUMA), Allogene Therapeutics (ALLO), Prime Medicine (PRME), ProKidney (PROK), and Editas Medicine (EDIT). These companies are all part of the "biological products, except diagnostic" industry.
Alector (NASDAQ:ALEC) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, community ranking, media sentiment and profitability.
85.8% of Alector shares are owned by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are owned by institutional investors. 14.0% of Alector shares are owned by company insiders. Comparatively, 5.0% of Fate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Fate Therapeutics had 10 more articles in the media than Alector. MarketBeat recorded 13 mentions for Fate Therapeutics and 3 mentions for Alector. Alector's average media sentiment score of 0.13 beat Fate Therapeutics' score of -0.25 indicating that Fate Therapeutics is being referred to more favorably in the news media.
Alector currently has a consensus target price of $14.50, indicating a potential upside of 176.19%. Fate Therapeutics has a consensus target price of $6.73, indicating a potential upside of 77.03%. Given Fate Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Alector is more favorable than Fate Therapeutics.
Alector has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500.
Alector has a net margin of -134.34% compared to Alector's net margin of -253.30%. Alector's return on equity of -38.17% beat Fate Therapeutics' return on equity.
Alector has higher revenue and earnings than Fate Therapeutics. Alector is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.
Fate Therapeutics received 334 more outperform votes than Alector when rated by MarketBeat users. Likewise, 69.08% of users gave Fate Therapeutics an outperform vote while only 60.25% of users gave Alector an outperform vote.
Summary
Alector and Fate Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get Fate Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FATE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fate Therapeutics Competitors List
Related Companies and Tools
